Oncotelic Therapeutics (OTCQB: OTLC) and its wholly owned subsidiary Pet2DAO, Inc. have issued an open invitation to scientists, AI developers, and biotech founders to participate in BIO REBOOT, an initiative built around the company's PDAOAI artificial intelligence-powered drug discovery platform. The move matters because it shifts AI drug discovery from a proprietary, in-house exercise to a community-driven model where external researchers can bring their own questions, technical expertise, and drug discovery ideas into the PDAOAI ecosystem. Selected projects may be considered for startup funding as well as Oncotelic support covering validation, formulation, regulatory planning, and clinical development. That combination of capital and operational guidance could lower the barriers that typically keep promising computational discoveries from reaching the clinic, especially for small teams that lack the resources to navigate regulatory and formulation hurdles on their own.
The company also announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, scheduled for Oct. 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will present a hepatocellular carcinoma case study showing how Partitioned Literature Aggregation generated a candidate four-gene signature. Product Manager Scott Myers will discuss AI search aggregation for biomedical knowledge discovery in drug development. These presentations are significant because they offer concrete evidence that the platform can produce biologically meaningful outputs, not just data summaries. A four-gene signature for hepatocellular carcinoma, a cancer with substantial unmet need, illustrates how AI can distill vast literature into testable hypotheses that may guide therapy selection or development.
Oncotelic develops oncology and immunotherapy products, focusing on cancers with substantial unmet needs and rare pediatric indications. The company also develops the PDAOAI platform to support its drug discovery and development work. For investors and industry observers, BIO REBOOT signals that Oncotelic is positioning PDAOAI as more than an internal tool; it is becoming a potential hub for external innovation. If the model succeeds, it could create a pipeline of partnered programs and strengthen the company's competitive position in AI-assisted oncology. Full details are available in the company's press release at https://ibn.fm/dxB7y, and ongoing updates are available in the company's newsroom at https://ibn.fm/OTLC.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and editorial syndication to 5,000+ outlets, among other services. For those tracking the intersection of AI and drug development, the BIO REBOOT invitation is a notable test of whether open collaboration can accelerate the translation of computational insights into real therapies.
